France's Innate Pharma has signed a deal to pay Novo Nordisk ($NVO) $2.7 million up front and as much as $27 million in milestones for exclusive rights to the pair's Phase II-ready cancer immunotherapy. Under the agreement, Innate gets IPH2201--a drug that blocks the checkpoint receptor NKG2A to spur cancer cell death--developed through a multiyear research collaboration between the two. More